New Late-Breaking Results from Phase 3 Trials of SKYRIZI® Evaluating Long-term Effect on Skin and Joint Symptoms in Patients with Psoriatic Arthritis at Week 100 Pharmaceutical Investing
Bristol Myers Squibb Announces New Sotyktu Long-Term Data Showing Clinical Efficacy Maintained for Up to Two Years with Continuous Treatment in Moderate-to-Severe Plaque Psoriasis Pharmaceutical Investing
Merck and Eisai Present Results From Phase 3 LEAP-002 Trial Evaluating KEYTRUDA® Plus LENVIMA® Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma Life Science Investing
  U.S. Food and Drug Administration Approves Sotyktu , Oral Treatment for Adults with Moderate-to-Severe Plaque Psoriasis Pharmaceutical Investing
LYNPARZA® in Combination With Bevacizumab, and as Monotherapy, Demonstrates Clinically Meaningful Long-Term Survival in Certain Patients With First-Line Advanced Ovarian Cancer in Exploratory Analyses of Two Phase 3 Trials Life Science Investing
Bausch Health Responds to Norwich Pharmaceuticals Tentative FDA Approval for a 200 mg Rifaximin Pharmaceutical Investing
FDA and EMA Accept Regulatory Submission for Pfizer's Ritlecitinib for Individuals 12 Years and Older with Alopecia Areata Life Science Investing
Bausch Health Clarifies Release Provisions Related to its Exchange Offers and Consent Solicitations Pharmaceutical Investing
Merck Foundation Launches $20 Million Initiative to Advance Equity in U.S. Cancer Care Life Science Investing
Three-Year Data on World's Smallest Heart Device Show Benefits of Fixing Holes in Newborn Hearts Without Surgery Pharmaceutical Investing
